Most azole resistance mutations in the Candida albicans drug target confer cross-resistance without intrinsic fitness cost
Camille Bédard, Isabelle Gagnon‐Arsenault, Jonathan Boisvert, Samuel Plante, Alexandre K. Dubé, Alicia Pageau, Anna Fijarczyk, Jehoshua Sharma, Laetitia Maroc, Rebecca S. Shapiro, Christian R. Landry
Topics & Concepts
Candida albicansDrug resistanceCross-resistanceAzoleResistance (ecology)BiologyDrugMicrobiologyGeneticsAntifungalPharmacologyEcologyAntifungal resistance and susceptibilityPneumocystis jirovecii pneumonia detection and treatmentAntibiotic Resistance in Bacteria